Syndrome

BASICS


DESCRIPTION


• Ehlers–Danlos syndrome is a group of connective tissue disorders characterized by joint hypermobility, hyperextensible skin, and fragile connective tissue.


• New classification system describes 6 types:


– Classic type (formerly types I and II, characterized by joint hypermobility, skin laxity and fragility).


– Hypermobility type (formerly type III, characterized by joint hypermobility).


– Vascular type (formerly type IV, complicated by arterial or bowel rupture).


– Kyphoscoliosis type (formerly type VI or ocular-scoliotic type, characterized by globe fragility, scoliosis, and skin and joint laxity).


– Arthrochalasis type (formerly type VIIB, characterized by short stature, joint laxity and dislocations).


– Dermatosparaxis type (formerly type VIIC, characterized by fragile skin with sagging and folding).


– Tenascin-X-deficient type (characterized by joint hypermobility, hyperelastic skin, and fragile tissue).


EPIDEMIOLOGY


Prevalence


• The prevalence of Ehlers–Danlos syndrome is reported to be 1 in 5,000–10,000 individuals. However, the disease may be underdiagnosed due to milder presentations.


– The kyphoscoliosis type affects 2% and is 1 of the less common types.


RISK FACTORS


Genetics


• Varies by type: the kyphoscoliosis and the dermatosparaxis types are autosomal recessive, and the remaining types are autosomal dominant.


• The ADAMTS2, COL1A2, COL3A1, COL5A1, COL5A2, PLOD1, and TNXB genes are all associated with Ehlers–Danlos.


– These genes are responsible for the assembly and modification of collagen molecules.


GENERAL PREVENTION


Genetic counseling.


PATHOPHYSIOLOGY


Gene mutations result in deficient collagen biosynthesis, primarily of types I and III, leading to fragility of collagen-containing structures.


ETIOLOGY


The various types of Ehlers–Danlos syndrome are due to mutations in many genes coding for collagen synthesis or posttranslational modification.


DIAGNOSIS


HISTORY


• Family history.


• Muscle weakness.


• Joint pain.


• Easy bruising.


• Dental problems.


• Ocular problems.


PHYSICAL EXAM


• Skin usually white, soft, doughy, hyperextensible, fragile, and with visible underlying vessels.


• Flexible fingers and toes.


• Molluscoid pseudotumors—spongy tumors overlying scars


• Cardiac defects.


– Mitral valve prolapse.


– Dysautonomia.


• Abnormal wound healing.


• Increased bleeding (platelet aggregation dysfunction).


• Ocular defects.


– Retinal hemorrhage.


– Retinal detachment (due to stretching of collagenous sclera).


– Keratoconus.


– Lens subluxation.


– Angioid streaks.


– Dry eyes.


– Strabismus.


– Glaucoma.


– Blue sclera.


– Carotid–cavernous sinus fistula.


– Globe rupture.


– Myopia.


– Posterior staphyloma.


– Photophobia.


• Musculoskeletal features.


– Hyperextensible joints.


– Spontaneous dislocation.


– Sprain.


– Subluxation.


– Kyphoscoliosis (convex curving of the spinal column both backwards and sideways).


– Hallus valgus (bunion).


– Pes planus (flat foot).


– Genu recurvatum (hyperextension of knee).


• Functional bowel disorder.


– Gastritis.


– Irritable bowel syndrome.


• Nerve compression (carpal tunnel).


DIAGNOSTIC TESTS & INTERPRETATION


Lab


• No screening laboratory tests.


• Secondary laboratory testing includes the following:


– Collagen typing.


– Collagen gene mutation testing (see “Genetics”).


– Lysyl oxidase or hydroxylase activity.


Imaging


• No initial imaging.


• Secondary imaging may show:


– Calcification of nodules opaque on radiographs.


– Joint dislocation/subluxation.


Diagnostic Procedures/Other


• Echocardiography (mitral valve prolapse).


• Skin biopsy (not sensitive).


Pathological Findings


• Histology reveals whorled, sparse, and disorderly collagen.


• Irregular diameter of fibrils.


DIFFERENTIAL DIAGNOSIS


• Elastolysis.


• Loeys–Dietz syndrome.


• Pseudoxanthoma elasticum.


• Turner syndrome.


• Cartilage-hair hypoplasia syndrome.


• Muscular hypotonia.


TREATMENT


MEDICATION


First Line


• Unsatisfactory medical treatments.


• Treatment is largely supportive.


Second Line


• Vitamin C—cofactor for collagen fibril synthesis.


ADDITIONAL TREATMENT


General Measures


• Care with surgery (vascular rupture and increased bleeding risk).


• Care with anesthesia (cervical spine and airway trauma).


• Avoidance of contact sports (types IV and VI) due to spontaneous vascular rupture.


• Care with pregnancy—reports of premature rupture of membranes.


Issues for Referral


• Ophthalmology.


• Dental.


• Orthopedics.


ONGOING CARE


FOLLOW-UP RECOMMENDATIONS


• Ophthalmology.


• Primary care doctor or dermatologist for periodic skin examinations.


• Orthopedics (braces, surgical repair of joints).


• Rehabilitation (physical and occupational therapy).


• Genetic counseling prior to pregnancy.


PATIENT EDUCATION


• The Ehlers–Danlos National Foundation (http://www.ednf.org).


PROGNOSIS


• Generally patients have a normal lifespan.


• Risk of large vessel or organ rupture with the vascular and kyphoscoliosis types with possible sudden death.


COMPLICATIONS


• Organ rupture (uterus or bowel).


• Vessel rupture (aortic aneurysm).


• Globe rupture.


• Arthritis.


ADDITIONAL READING


• Beighton P. Serious Ophthalmological complications in the Ehlers-Danlos syndrome. Br J Ophthalmol 54(4):263–268.


• Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos Syndromes: Revised Nosology, Villefranche, 1997. Am J Med Genet 77:31–37.


• Pollack JS, Custer PL, Hart WM, Smith ME, Fitzpatrick MM. Ocular Complications in Ehlers-Danlos Syndrome Type IV. Arch Opthalmol 115:416–419.


CODES


ICD9


361.9 Unspecified retinal detachment


362.81 Retinal hemorrhage


756.83 Ehlers-danlos syndrome


CLINICAL PEARLS


• Ehlers–Danlos is underdiagnosed because of varied presentation.


• The vascular type of Ehlers–Danlos may not present with joint hypermobility or skin hyperelasticity.


• Ehlers–Danlos syndrome is primarily a clinical diagnosis, and most individuals will not likely have any symptoms throughout their lifetime.


Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Nov 9, 2016 | Posted by in OPHTHALMOLOGY | Comments Off on Syndrome

Full access? Get Clinical Tree

Get Clinical Tree app for offline access